Harvard
Sepriano, A, Ramiro, S, FitzGerald, O
, Østergaard, M, Homik, J, van der Heijde, D, Elkayam, O, Thorne, C, Larché, MJ, Ferraccioli, G, Backhaus, M, Burmester, GR, Boire, G, Combe, B, Saraux, A, Dougados, M, Rossini, M, Govoni, M, Sinigaglia, L, Cantagrel, A, Barnabe, C, Bingham, CO, Tak, PP, van Schaardenburg, D, Hammer, HB, Paschke, J, Dadashova, R, Hutchings, E, Landewé, R & Maksymowych, WP 2020, '
Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort'
Journal of Rheumatology, vol. 47, no. 6, pp. 809-819.
https://doi.org/10.3899/jrheum.190303APA
Sepriano, A., Ramiro, S., FitzGerald, O.
, Østergaard, M., Homik, J., van der Heijde, D., ... Maksymowych, W. P. (2020).
Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.
Journal of Rheumatology,
47(6), 809-819.
https://doi.org/10.3899/jrheum.190303CBE
Sepriano A, Ramiro S, FitzGerald O
, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP. 2020.
Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.
Journal of Rheumatology. 47(6):809-819.
https://doi.org/10.3899/jrheum.190303MLA
Vancouver
Author
Sepriano, Alexandre ; Ramiro, Sofia ; FitzGerald, Oliver
; Østergaard, Mikkel ; Homik, Joanne ; van der Heijde, Désirée ; Elkayam, Ori ; Thorne, Carter ; Larché, Maggie J ; Ferraccioli, Gianfranco ; Backhaus, Marina ; Burmester, Gerd R ; Boire, Gilles ; Combe, Bernard ; Saraux, Alain ; Dougados, Maxime ; Rossini, Maurizio ; Govoni, Marcello ; Sinigaglia, Luigi ; Cantagrel, Alain ; Barnabe, Cheryl ; Bingham, Clifton O ; Tak, Paul P ; van Schaardenburg, Dirkjan ; Hammer, Hilde Berner ; Paschke, Joel ; Dadashova, Rana ; Hutchings, Edna ; Landewé, Robert ; Maksymowych, Walter P. /
Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors : Data from the International RA BIODAM Cohort. In:
Journal of Rheumatology. 2020 ; Vol. 47, No. 6. pp. 809-819.
Bibtex
@article{9c3f3de2ee6f4e089c906e897cdab78b,
title = "Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort",
abstract = "OBJECTIVE: Compelling evidence supports a treat-to-target (T2T) strategy for optimal outcomes in rheumatoid arthritis (RA). There is limited knowledge regarding the factors that impede implementation of T2T, particularly in a setting where adherence to T2T is protocol-specified. We aimed to assess clinical factors that associate with failure to adhere to T2T.METHODS: Patients with RA from 10 countries who were starting or changing conventional synthetic disease-modifying antirheumatic drugs and/or starting tumor necrosis factor inhibitors were followed for 2 years. Participating physicians were required per protocol to adhere to the T2T strategy. Factors influencing adherence to T2T low disease activity (T2T-LDA; 44-joint count Disease Activity Score ≤ 2.4) were analyzed in 2 types of binomial generalized estimating equations models: (1) including only baseline features (baseline model); and (2) modeling variables that inherently vary over time as such (longitudinal model).RESULTS: A total of 571 patients were recruited and 439 (76.9{\%}) completed 2-year followup. Failure of adherence to T2T-LDA was noted in 1765 visits (40.5{\%}). In the baseline multivariable model, a high number of comorbidities (OR 1.10, 95{\%} CI 1.02-1.19), smoking (OR 1.32, 95{\%} CI 1.08-1.63) and high number of tender joints (OR 1.03, 95{\%} CI 1.02-1.04) were independently associated with failure to implement T2T, while anticitrullinated protein antibody/rheumatoid factor positivity (OR 0.63, 95{\%} CI 0.50-0.80) was a significant facilitator of T2T. Results were similar in the longitudinal model.CONCLUSION: Lack of adherence to T2T in the RA BIODAM cohort was evident in a substantial proportion despite being a protocol requirement, and this could be predicted by clinical features. [Rheumatoid Arthritis (RA) BIODAM cohort; ClinicalTrials.gov: NCT01476956].",
author = "Alexandre Sepriano and Sofia Ramiro and Oliver FitzGerald and Mikkel {\O}stergaard and Joanne Homik and {van der Heijde}, D{\'e}sir{\'e}e and Ori Elkayam and Carter Thorne and Larch{\'e}, {Maggie J} and Gianfranco Ferraccioli and Marina Backhaus and Burmester, {Gerd R} and Gilles Boire and Bernard Combe and Alain Saraux and Maxime Dougados and Maurizio Rossini and Marcello Govoni and Luigi Sinigaglia and Alain Cantagrel and Cheryl Barnabe and Bingham, {Clifton O} and Tak, {Paul P} and {van Schaardenburg}, Dirkjan and Hammer, {Hilde Berner} and Joel Paschke and Rana Dadashova and Edna Hutchings and Robert Landew{\'e} and Maksymowych, {Walter P}",
year = "2020",
month = "6",
day = "1",
doi = "10.3899/jrheum.190303",
language = "English",
volume = "47",
pages = "809--819",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology Publishing Co. Ltd",
number = "6",
}
RIS
TY - JOUR
T1 - Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors
T2 - Data from the International RA BIODAM Cohort
AU - Sepriano, Alexandre
AU - Ramiro, Sofia
AU - FitzGerald, Oliver
AU - Østergaard, Mikkel
AU - Homik, Joanne
AU - van der Heijde, Désirée
AU - Elkayam, Ori
AU - Thorne, Carter
AU - Larché, Maggie J
AU - Ferraccioli, Gianfranco
AU - Backhaus, Marina
AU - Burmester, Gerd R
AU - Boire, Gilles
AU - Combe, Bernard
AU - Saraux, Alain
AU - Dougados, Maxime
AU - Rossini, Maurizio
AU - Govoni, Marcello
AU - Sinigaglia, Luigi
AU - Cantagrel, Alain
AU - Barnabe, Cheryl
AU - Bingham, Clifton O
AU - Tak, Paul P
AU - van Schaardenburg, Dirkjan
AU - Hammer, Hilde Berner
AU - Paschke, Joel
AU - Dadashova, Rana
AU - Hutchings, Edna
AU - Landewé, Robert
AU - Maksymowych, Walter P
PY - 2020/6/1
Y1 - 2020/6/1
N2 - OBJECTIVE: Compelling evidence supports a treat-to-target (T2T) strategy for optimal outcomes in rheumatoid arthritis (RA). There is limited knowledge regarding the factors that impede implementation of T2T, particularly in a setting where adherence to T2T is protocol-specified. We aimed to assess clinical factors that associate with failure to adhere to T2T.METHODS: Patients with RA from 10 countries who were starting or changing conventional synthetic disease-modifying antirheumatic drugs and/or starting tumor necrosis factor inhibitors were followed for 2 years. Participating physicians were required per protocol to adhere to the T2T strategy. Factors influencing adherence to T2T low disease activity (T2T-LDA; 44-joint count Disease Activity Score ≤ 2.4) were analyzed in 2 types of binomial generalized estimating equations models: (1) including only baseline features (baseline model); and (2) modeling variables that inherently vary over time as such (longitudinal model).RESULTS: A total of 571 patients were recruited and 439 (76.9%) completed 2-year followup. Failure of adherence to T2T-LDA was noted in 1765 visits (40.5%). In the baseline multivariable model, a high number of comorbidities (OR 1.10, 95% CI 1.02-1.19), smoking (OR 1.32, 95% CI 1.08-1.63) and high number of tender joints (OR 1.03, 95% CI 1.02-1.04) were independently associated with failure to implement T2T, while anticitrullinated protein antibody/rheumatoid factor positivity (OR 0.63, 95% CI 0.50-0.80) was a significant facilitator of T2T. Results were similar in the longitudinal model.CONCLUSION: Lack of adherence to T2T in the RA BIODAM cohort was evident in a substantial proportion despite being a protocol requirement, and this could be predicted by clinical features. [Rheumatoid Arthritis (RA) BIODAM cohort; ClinicalTrials.gov: NCT01476956].
AB - OBJECTIVE: Compelling evidence supports a treat-to-target (T2T) strategy for optimal outcomes in rheumatoid arthritis (RA). There is limited knowledge regarding the factors that impede implementation of T2T, particularly in a setting where adherence to T2T is protocol-specified. We aimed to assess clinical factors that associate with failure to adhere to T2T.METHODS: Patients with RA from 10 countries who were starting or changing conventional synthetic disease-modifying antirheumatic drugs and/or starting tumor necrosis factor inhibitors were followed for 2 years. Participating physicians were required per protocol to adhere to the T2T strategy. Factors influencing adherence to T2T low disease activity (T2T-LDA; 44-joint count Disease Activity Score ≤ 2.4) were analyzed in 2 types of binomial generalized estimating equations models: (1) including only baseline features (baseline model); and (2) modeling variables that inherently vary over time as such (longitudinal model).RESULTS: A total of 571 patients were recruited and 439 (76.9%) completed 2-year followup. Failure of adherence to T2T-LDA was noted in 1765 visits (40.5%). In the baseline multivariable model, a high number of comorbidities (OR 1.10, 95% CI 1.02-1.19), smoking (OR 1.32, 95% CI 1.08-1.63) and high number of tender joints (OR 1.03, 95% CI 1.02-1.04) were independently associated with failure to implement T2T, while anticitrullinated protein antibody/rheumatoid factor positivity (OR 0.63, 95% CI 0.50-0.80) was a significant facilitator of T2T. Results were similar in the longitudinal model.CONCLUSION: Lack of adherence to T2T in the RA BIODAM cohort was evident in a substantial proportion despite being a protocol requirement, and this could be predicted by clinical features. [Rheumatoid Arthritis (RA) BIODAM cohort; ClinicalTrials.gov: NCT01476956].
U2 - 10.3899/jrheum.190303
DO - 10.3899/jrheum.190303
M3 - Journal article
VL - 47
SP - 809
EP - 819
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 6
ER -
